Since the therapeutic efficacy of the adjuvants included in immune-targeting Abs has been widely shown in the treatment of cancer, we hypothesized that the use of DTA-1, as an enhancer of tumor-specific CD8+ T cell responses [26], [27] in HF10 virotherapy might produce a satisfactory treatment outcome. This evidence concerns the gene CD8A and cancer.